Breaking News

Financial Report: Allergan

May 7, 2014

Specialty pharma sales up 10% in the quarter

1Q Revenues: $1.6 billion (+13%)

1Q Earnings: $257.9 million (earnings were $14.4 million in 1Q13)

Comments: Specialty pharmaceuticals sales increased 10% to $1.4 billion, with Eye Care Pharmaceutical sales of $730.4 million, up 9%, and Botox/Neuromodulators sales up 10% to $501.8 million. Medical devices sales increased 29% to $259.8 million. Earnings in 1Q13 include $258.6 million from discontinued operations associated with the sale of the obesity intervention business unit. On April 22, Allergan received an unsolicited proposal from Valeant Pharmaceuticals to acquire all outstanding shares of Allergan for approximately $47 billion. The Allergan board is currently reviewing the proposal.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.